|
Sub-category:
Allogeneic Bone Marrow Transplantation
Category:
Transplantation
Meeting:
2003 ASCO Annual Meeting
Session Type and Session Title:
Oral Presentation, Advances in Stem Cell Transplantation
Abstract No:
3345
Citation:
Proc Am Soc Clin Oncol 22: 2003 (abstr 3345)
Author(s):
N. T. Ueno, J. D. Rizzo, U. Hegenbart, Y. C. Cheng, G. Rondón, K. Antman, P. J. Stiff, T. Demirer, M. M. Horowitz, D. Niederwieser, IBMTR & EBMT Solid Tumor Working Committees; International Bone Marrow Transplant Registry (IBMTR)/Autologous Blood and Marrow Transplant Registry (ABMTR), The European Group for Blood and Marrow Transplantation (EBMT), Medical College of Wisconsin, Milwaukee, WI
Abstract:
To determine the feasibility and efficacy of Allo HSCT for MBC, we reviewed registry data from 18 IBMTR/EBMT centers on patients with MBC who underwent Allo HSCT between 1992 and 2000. Rates of treatment-related mortality (TRM), graft-vs-host disease (GVHD), overall survival and time to progression and progression-free survival (PFS) were determined. Kaplan-Meier analysis was used to determine survival probability. Seventy-six patients were identified from the registry; median age at transplant was 41 years (range, 25-60) and median follow-up for the survivors was 25 months. At the time of transplantation, 28 patients (37%) had responsive disease (20 partial responses), 22 (29%) had stable disease, and 18 (24%) had progressive disease. Of the 76 patients, 66 patients (87%) received stem cells from a matched sibling and 2 patients (3%) from an unrelated donor. Sixty-eight patients (90%) received peripheral blood stem cells and 6 patients (8%) received bone marrow cells. Conditioning regimens are listed in the table. Acute GVHD occurred in 39 patients (51%) and was grade III-IV in 14 patients (36%). Chronic GVHD occurred in 19 patients (25%). TRM at day 100 was 22%. Overall survival at 2 years was 22%. Median survival time and median time to progression were both 8 months; 15% remained free of progression at 2 years. PFS at 2 years was 9%, with median PFS of 4 months. Univariate analysis revealed that the presence of any GVHD (acute or chronic) was associated with longer time to progression (11 vs 3 mo, P=0.03), but GVHD had no effect on overall survival or PFS. We conclude that Allo HSCT is feasible in MBC with acceptable TRM. Although most patients had chemoresistant disease, those who developed any GVHD had longer time to progression, suggesting the presence of a graft-vs-breast cancer effect. Further details of the analysis will be presented.
|
Regimen |
Cy, BCNU, Thio |
Flu, Cy |
Cy, Thio, Carbo |
Cy, Thio, Flu |
Cy, Cis based |
Others |
|
# |
22 |
11 |
7 |
7 |
5 |
24 |
|
Cy: Cyclophosphamide, BCNU: Carmustine, Thio: Thiotepa, Flu: Fludarabine, Carbo: Carboplatin, Cis: Cisplatin |
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by N. T. Ueno:
Presentations by N. T. Ueno:
Educational Book Manuscripts by N. T. Ueno:
|
